Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 2/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18793267 | 0.76 | CA3 (0.46) | ALDH1A1NFE2L2TDP1 | |
| SCHEMBL18086857 | 0.74 | RAD51 (0.41) | ALDH1A1 | |
| SCHEMBL8054621 | 0.74 | ERN1 (0.38) | ALDH1A1KDM4EPTPN1ERN1PTGS2 | |
| SCHEMBL535964 | 0.72 | LMNA (0.50) | ALDH1A1PTPN1ERN1TDP1TRIM24 | |
| SCHEMBL8066110 | 0.72 | NFE2L2 (0.45) | NFE2L2PTGS2 | |
| SCHEMBL8066115 | 0.72 | NFE2L2 (0.45) | NFE2L2PTGS2 | |
| SCHEMBL11819766 | 0.72 | NFE2L2 (0.45) | NFE2L2PTGS2 | |
| SCHEMBL4363014 | 0.71 | ERN1 (0.46) | ALDH1A1KDM4EPTPN1ERN1NFE2L2 | |
| SCHEMBL29957006 | 0.71 | ERN1 (0.46) | ALDH1A1KDM4EPTPN1ERN1NFE2L2 | |
| SCHEMBL8054634 | 0.71 | PDE7A (0.35) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | ALDH1A1 563/4885KDM4E 702/4885PTPN1 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.